HUNAN FANGSHENG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.27 CNY | +3.30% |
|
+8.26% | +2.83% |
| Apr. 19 | Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 10 | Fangsheng Pharma's Factories Pass GMP Inspection | MT |
| Sales 2023 | 1.63B 225M | Sales 2024 * | 2.1B 290M | Capitalization | 4.95B 684M |
|---|---|---|---|---|---|
| Net income 2023 | 187M 25.8M | Net income 2024 * | 225M 31.05M | EV / Sales 2023 | 2.96 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 2.36 x |
| P/E ratio 2023 |
26.1
x | P/E ratio 2024 * |
22.1
x | Employees | 1,600 |
| Yield 2023 |
1.82% | Yield 2024 * |
0.89% | Free-Float | 59.54% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.30% | ||
| 1 week | +8.26% | ||
| Current month | +0.18% | ||
| 1 month | +1.81% | ||
| 3 months | +14.65% | ||
| 6 months | +14.07% | ||
| Current year | +2.83% |
1 week
10.23
11.58
1 month
10.1211.58
Current year
7.1211.94
1 year
7.1214.73
3 years
4.8914.73
5 years
4.7714.73
10 years
4.5021.70
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Li Zhou
CEO | Chief Executive Officer | 51 | - |
Zai Chang Liu
DFI | Director of Finance/CFO | 50 | 21-06-16 |
| 43 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xue Min Gao
BRD | Director/Board Member | 86 | 23-09-18 |
Shou Ying Du
BRD | Director/Board Member | 64 | 20-04-30 |
Xiong Yuan
BRD | Director/Board Member | 59 | 21-11-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 11.27 | +3.30% | 13,255,060 |
| 24-04-19 | 10.91 | +4.40% | 5,946,013 |
| 24-04-18 | 10.45 | -1.23% | 3,242,431 |
| 24-04-17 | 10.58 | +4.44% | 5,221,331 |
| 24-04-16 | 10.13 | -2.69% | 6,359,400 |
End-of-day quote Shanghai S.E., April 21, 2024
More quotes
Hunan FangshengPharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, production and sale of cardiovascular medicine, orthopedic medicine, pediatric medicine, gynecological medicine and anti-infective medicine. The Company's main products include Xuesaitong Dispersible Tablets, Xuesaitong Tablets, Tenghuang Jiangu Tablets, Dieda Huoxue Capsules, Lysine Dimension B12 Granules, Cefixoxime Tablets and Jinying Capsules. The Company distributes its products primarily in domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-28
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.27
CNY
Average target price
10.31
CNY
Spread / Average Target
-8.52%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +2.83% | 684M | |
| +18.00% | 44.31B | |
| +19.87% | 22.17B | |
| +14.93% | 14.62B | |
| +8.08% | 13.12B | |
| +39.41% | 11.58B | |
| -8.96% | 6.96B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.50% | 5.03B |
- Stock Market
- Equities
- 603998 Stock
